CN114269345B - Alk2抑制剂的晶体形式 - Google Patents

Alk2抑制剂的晶体形式 Download PDF

Info

Publication number
CN114269345B
CN114269345B CN201980086179.8A CN201980086179A CN114269345B CN 114269345 B CN114269345 B CN 114269345B CN 201980086179 A CN201980086179 A CN 201980086179A CN 114269345 B CN114269345 B CN 114269345B
Authority
CN
China
Prior art keywords
bmp
compound
crystalline compounds
activity
compositions described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980086179.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114269345A (zh
Inventor
S·贝图恩
K·迪亚斯
C·A·埃文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keros Therapeutics Inc
Original Assignee
Keros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keros Therapeutics Inc filed Critical Keros Therapeutics Inc
Publication of CN114269345A publication Critical patent/CN114269345A/zh
Application granted granted Critical
Publication of CN114269345B publication Critical patent/CN114269345B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980086179.8A 2018-10-26 2019-10-25 Alk2抑制剂的晶体形式 Active CN114269345B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751255P 2018-10-26 2018-10-26
US62/751255 2018-10-26
PCT/US2019/058062 WO2020086963A1 (en) 2018-10-26 2019-10-25 Crystal forms of an alk2 inhibitor

Publications (2)

Publication Number Publication Date
CN114269345A CN114269345A (zh) 2022-04-01
CN114269345B true CN114269345B (zh) 2025-06-27

Family

ID=70330555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980086179.8A Active CN114269345B (zh) 2018-10-26 2019-10-25 Alk2抑制剂的晶体形式

Country Status (8)

Country Link
US (1) US12071438B2 (https=)
EP (1) EP3870181B1 (https=)
JP (2) JP7504880B2 (https=)
CN (1) CN114269345B (https=)
AU (1) AU2019364631B2 (https=)
CA (1) CA3117695A1 (https=)
WO (1) WO2020086963A1 (https=)
ZA (1) ZA202103228B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
JP2024509376A (ja) * 2021-02-18 2024-03-01 ベレン セラピューティクス ピー．ビー．シー． 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200855A1 (en) * 2017-04-27 2018-11-01 The Brigham And Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20190055192A1 (en) 2004-06-07 2019-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
PT1812440E (pt) 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
WO2006088972A2 (en) 2005-02-16 2006-08-24 The General Hospital Corporation Use of modulatirs of compounds of tgf-beta superfamily to regulate hepcidin-mediated iron metabolism
CA2631312A1 (en) 2005-11-29 2007-06-07 Nevada Cancer Institute Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
CN105503882B (zh) * 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
WO2014160203A2 (en) * 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CN109311889B (zh) 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CU20200035A7 (es) 2017-11-24 2021-03-11 Novartis Ag Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
CN113366019B (zh) 2018-10-23 2024-08-27 科乐斯疗法公司 Alk2抗体及其使用方法
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
TWI870440B (zh) 2019-08-13 2025-01-21 美商纜圖藥品公司 活化素受體樣激酶抑制劑之鹽及晶體形式
ES3014839T3 (en) 2019-10-02 2025-04-25 Blueprint Medicines Corp Process for preparing an activin receptor-like kinase inhibitor
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022098821A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022099166A1 (en) 2020-11-09 2022-05-12 Keros Therapeutics, Inc. Methods of treating cardiovascular-related disease
US20250034148A1 (en) 2021-11-02 2025-01-30 Keros Therapeutics, Inc. Methods of using alk2 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200855A1 (en) * 2017-04-27 2018-11-01 The Brigham And Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Also Published As

Publication number Publication date
JP2022512824A (ja) 2022-02-07
JP2024107352A (ja) 2024-08-08
ZA202103228B (en) 2025-08-27
AU2019364631A1 (en) 2021-06-03
WO2020086963A1 (en) 2020-04-30
EP3870181A4 (en) 2022-07-20
AU2019364631B2 (en) 2025-05-01
US20210238185A1 (en) 2021-08-05
EP3870181A1 (en) 2021-09-01
US12071438B2 (en) 2024-08-27
EP3870181B1 (en) 2024-08-14
CA3117695A1 (en) 2020-04-30
CN114269345A (zh) 2022-04-01
JP7504880B2 (ja) 2024-06-24

Similar Documents

Publication Publication Date Title
CN114269345B (zh) Alk2抑制剂的晶体形式
US10583143B2 (en) Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
KR102092988B1 (ko) 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
CN111164083B (zh) 用于抑制bmp信号传导的新型alk2抑制剂和方法
EA032596B1 (ru) Соли, способ их получения и их применение для лечения воспалительных заболеваний
JP2016510745A (ja) Ｂｍｐ阻害剤およびその使用方法
US8883763B2 (en) Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same
JP2014504604A (ja) 心血管疾患のための組成物および方法
CN106536520A (zh) 芳基受体调制剂及其制备和使用方法
PT2663564E (pt) Composto de imidazo[4,5-c]quinolin-2-ona e a sua utilização como inibidor dual de quinase pi3/mtor
JP2023516645A (ja) Ｔｅａｄ阻害剤としてのヘテロ二官能性分子
US20100099106A1 (en) Cell death inhibitor
EP4236941A1 (en) Nmt inhibitors for treating senescence-associated diseases or disorders
WO2018053373A1 (en) Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
JP6553081B2 (ja) アダプター関連キナーゼ１の阻害剤、それを含む組成物、及びその使用方法
CA3078247A1 (en) Methods and compositions for treating urea cycle disorders, in particular otc deficiency
JP6909236B2 (ja) キナゾリン誘導体またはその塩およびそれを含む医薬組成物
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
EP3475274A1 (en) Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation
CN121079296A (zh) α-v-β-8整合素抑制剂及其用途
US9273006B2 (en) Anabolic compounds for treating and preventing bone loss diseases
KR20080106226A (ko) 신경계 장애의 치료에 있어서 피라졸로[1,5ａ]피리미딘-7-일 아민 유도체의 용도
EA028800B1 (ru) Комбинация производного имидазопиридазина и митотического средства для лечения рака
EP3706776A1 (en) Immunogenic compositions and uses therefor
JP2021031455A (ja) Ｉｆｉｔｍ５の変異に起因する骨形成不全症を治療するための医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant